Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for ALLO

Stock NameAllogene Therapeutics Inc
TickerALLO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS0197701065

Show aggregate ALLO holdings

News associated with ALLO

Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $8.44
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages […] - 2025-09-08 02:18:43
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 4.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 264,065 shares of the company’s stock after buying an additional 10,489 shares during the quarter. Mitsubishi UFJ […] - 2025-08-14 05:33:06
Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $8.44
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average […] - 2025-08-14 02:15:04
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month […] - 2025-07-17 05:10:53
Vontobel Holding Ltd. Decreases Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Vontobel Holding Ltd. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 5.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 185,646 shares of the company’s stock after selling 9,811 shares during the period. Vontobel Holding Ltd.’s holdings in Allogene Therapeutics were worth $271,000 as of its most […] - 2025-07-09 05:02:59
Exchange Traded Concepts LLC Purchases 8,183 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Exchange Traded Concepts LLC lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 13.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,858 shares of the company’s stock after purchasing an additional 8,183 shares during the period. […] - 2025-06-25 04:58:50
Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Price Target at $8.44
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average […] - 2025-06-25 02:12:49
Ameriprise Financial Inc. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Ameriprise Financial Inc. lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 14.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 201,943 shares of the company’s stock after acquiring an additional 24,830 shares during the quarter. Ameriprise Financial Inc.’s holdings in Allogene Therapeutics were worth $430,000 as of its […] - 2025-06-05 04:22:51
Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Citizens Jmp
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) was downgraded by research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, Marketbeat reports. A number of other brokerages have also recently commented on ALLO. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 […] - 2025-05-16 02:35:02
Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $7.00 at Piper Sandler
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) had its price target decreased by Piper Sandler from $9.00 to $7.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. ALLO has been the subject of a number of other reports. Robert W. Baird decreased their target price on […] - 2025-05-16 02:34:58
Dimensional Fund Advisors LP Grows Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Dimensional Fund Advisors LP raised its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 30.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,561,626 shares of the company’s stock after purchasing an additional 831,146 shares during the quarter. Dimensional Fund Advisors […] - 2025-05-12 05:22:49
Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price […] - 2025-05-06 02:09:01
Legal & General Group Plc Decreases Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Legal & General Group Plc trimmed its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 112,235 shares of the company’s stock after selling 15,172 shares during the quarter. Legal & General Group Plc’s holdings in Allogene Therapeutics were worth $239,000 at the end […] - 2025-05-01 04:57:03
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,000,692 shares of the company’s stock after selling 327,007 shares during the period. Vanguard Group Inc.’s holdings in Allogene Therapeutics were worth $17,041,000 at the end […] - 2025-04-17 04:22:52
Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among […] - 2025-04-11 02:40:54
Allogene's ALLO-329 Granted Three FDA Fast Track Designations
(RTTNews) - Clinical-stage biotechnology company Allogene Therapeutics, Inc. (ALLO), Monday announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast Track Designations (FTD) from the U.S. Food and Drug Administration (FDA) for - 2025-04-07 12:57:11
Teacher Retirement System of Texas Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Teacher Retirement System of Texas raised its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 28.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 43,877 shares of the company’s stock after purchasing an additional 9,839 shares during the quarter. Teacher Retirement System of Texas’ holdings in Allogene Therapeutics were worth $93,000 […] - 2025-04-03 04:16:48
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 16.2% in February
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 39,100,000 shares, a growth of 16.2% from the February 13th total of 33,660,000 shares. Based on an average daily trading volume, of 5,120,000 […] - 2025-03-21 04:58:44
Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $8.00 at HC Wainwright
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price objective decreased by HC Wainwright from $9.00 to $8.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating […] - 2025-03-20 05:44:59
Head to Head Analysis: Allogene Therapeutics (NASDAQ:ALLO) and DBV Technologies (NASDAQ:DBVT)
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Analyst Ratings This is a breakdown of […] - 2025-02-24 04:14:49

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ALLO holdings

DateNumber of ALLO Shares HeldBase Market Value of ALLO SharesLocal Market Value of ALLO SharesChange in ALLO Shares HeldChange in ALLO Base ValueCurrent Price per ALLO Share HeldPrevious Price per ALLO Share Held
2025-11-11 (Tuesday)140,827USD 174,625USD 174,625
2025-11-10 (Monday)140,827ALLO holding increased by 374USD 166,176ALLO holding increased by 441USD 166,176374USD 441 USD 1.18 USD 1.18
2025-11-07 (Friday)140,453USD 165,735ALLO holding increased by 18259USD 165,7350USD 18,259 USD 1.18 USD 1.05
2025-11-06 (Thursday)140,453ALLO holding increased by 376USD 147,476ALLO holding decreased by -8009USD 147,476376USD -8,009 USD 1.05 USD 1.11
2025-11-05 (Wednesday)140,077USD 155,485USD 155,4850USD 0 USD 1.11 USD 1.11
2025-11-04 (Tuesday)140,077ALLO holding increased by 377USD 155,485ALLO holding decreased by -9361USD 155,485377USD -9,361 USD 1.11 USD 1.18
2025-11-03 (Monday)139,700USD 164,846ALLO holding decreased by -8382USD 164,8460USD -8,382 USD 1.18 USD 1.24
2025-10-31 (Friday)139,700USD 173,228ALLO holding increased by 4191USD 173,2280USD 4,191 USD 1.24 USD 1.21
2025-10-30 (Thursday)139,700ALLO holding increased by 1890USD 169,037ALLO holding increased by 909USD 169,0371,890USD 909 USD 1.21 USD 1.22
2025-10-29 (Wednesday)137,810ALLO holding increased by 754USD 168,128ALLO holding decreased by -4563USD 168,128754USD -4,563 USD 1.22 USD 1.26
2025-10-28 (Tuesday)137,056USD 172,691ALLO holding increased by 4112USD 172,6910USD 4,112 USD 1.26 USD 1.23
2025-10-27 (Monday)137,056USD 168,579ALLO holding increased by 4112USD 168,5790USD 4,112 USD 1.23 USD 1.2
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALLO by Blackrock for IE00BYXG2H39

Show aggregate share trades of ALLO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY3741.2301.160 1.167USD 437 1.64
2025-11-06BUY3761.1001.050 1.055USD 397 1.65
2025-11-04BUY3771.1701.050 1.062USD 400 1.65
2025-10-30BUY1,8901.2601.210 1.215USD 2,296 1.66
2025-10-29BUY7541.2201.280 1.274USD 961 1.66
2025-10-22SELL-1,4841.2101.270 1.264USD -1,876 1.67 Profit of 606 on sale
2025-10-20BUY7421.2901.330 1.326USD 984 1.68
2025-10-17BUY1,8491.2301.270 1.266USD 2,341 1.68
2025-10-15BUY2,9281.2701.300 1.297USD 3,798 1.68
2025-10-03BUY2,6461.3301.340 1.339USD 3,543 1.69
2025-10-02BUY3781.2901.290 1.290USD 488 1.69
2025-09-30BUY7521.2401.310 1.303USD 980 1.69
2025-09-26BUY7521.2501.260 1.259USD 947 1.70
2025-09-25BUY7521.2001.220 1.218USD 916 1.70
2025-09-24BUY11.2301.230 1.230USD 1 1.70
2025-09-18BUY3751.2101.230 1.228USD 461 1.71
2025-09-17BUY1,1281.1301.200 1.193USD 1,346 1.71
2025-08-20SELL-1,5041.0601.080 1.078USD -1,621 1.72 Profit of 972 on sale
2025-07-30BUY1,4681.2901.500 1.479USD 2,171 1.75
2025-07-17SELL-7401.2401.270 1.267USD -938 1.77 Profit of 370 on sale
2025-07-11SELL-3,0081.2801.330 1.325USD -3,986 1.78 Profit of 1,370 on sale
2025-07-07BUY1,1281.1601.230 1.223USD 1,380 1.80
2025-07-02BUY20,5701.2001.290 1.281USD 26,350 1.80
2025-06-11BUY7481.4501.500 1.495USD 1,118 1.83
2025-06-10BUY7461.4601.510 1.505USD 1,123 1.84
2025-06-04SELL-3741.2901.360 1.353USD -506 1.85 Profit of 186 on sale
2025-04-23BUY3731.6101.750 1.736USD 648 2.02
2025-04-10SELL-2,9761.3701.450 1.442USD -4,291 2.08 Profit of 1,907 on sale
2025-04-08SELL-3721.3601.570 1.549USD -576 2.10 Profit of 204 on sale
2025-04-07SELL-3721.4301.500 1.493USD -555 2.11 Profit of 228 on sale
2025-04-04SELL-1,8701.4401.460 1.458USD -2,726 2.11 Profit of 1,227 on sale
2025-04-01BUY1,4961.3701.450 1.442USD 2,157 2.13
2025-03-31SELL-1,1221.4601.500 1.496USD -1,679 2.14 Profit of 722 on sale
2025-03-21BUY12,4381.6201.640 1.638USD 20,373 2.18
2025-03-14SELL-5,3121.9402.100 2.084USD -11,070 2.21 Profit of 681 on sale
2025-03-07SELL-6642.1802.320 2.306USD -1,531 2.23 Loss of -54 on sale
2025-03-04SELL-3321.9001.920 1.918USD -637 2.24 Profit of 106 on sale
2025-02-25BUY6641.9902.150 2.134USD 1,417 2.26
2025-02-19SELL-3292.6003.780 3.662USD -1,205 2.26 Loss of -461 on sale
2025-02-13BUY9931.4101.440 1.437USD 1,427 2.28
2025-02-12BUY3311.4301.460 1.457USD 482 2.29
2025-02-11BUY1,3241.4001.480 1.472USD 1,949 2.31
2024-12-30SELL-14,4922.1002.170 2.163USD -31,346 2.54 Profit of 5,496 on sale
2024-11-18SELL-5,4932.1502.320 2.303USD -12,650 2.82 Profit of 2,821 on sale
2024-11-08SELL-3653.0803.260 3.242USD -1,183 2.80 Loss of -163 on sale
2024-10-21SELL-3702.8002.900 2.890USD -1,069 0.00 Loss of -1,069 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALLO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19274,84501,413,15619.4%
2025-09-18599,12227,1543,610,61716.6%
2025-09-17472,4884,0001,678,16428.2%
2025-09-16224,2585151,308,45717.1%
2025-09-15182,5864,333859,18121.3%
2025-09-12247,1200783,37731.5%
2025-09-11201,1630752,71326.7%
2025-09-10233,3910779,69429.9%
2025-09-09268,171400774,54634.6%
2025-09-08171,7330631,11627.2%
2025-09-05196,18301,076,63618.2%
2025-09-04375,67401,055,49835.6%
2025-09-03361,34201,713,47721.1%
2025-09-02131,6181041,693,1797.8%
2025-08-29788,93701,711,34646.1%
2025-08-28849,06804,416,13319.2%
2025-08-27153,736801673,55122.8%
2025-08-26269,26037,750809,50333.3%
2025-08-25457,74502,720,67516.8%
2025-08-22487,7905,2174,785,30010.2%
2025-08-21556,83923,2551,759,04031.7%
2025-08-20541,10801,374,89139.4%
2025-08-19405,57801,385,84329.3%
2025-08-18625,4514851,523,04041.1%
2025-08-151,026,8701,6033,288,87731.2%
2025-08-141,245,6982003,448,34636.1%
2025-08-13790,05404,585,03917.2%
2025-08-12443,5433821,179,22237.6%
2025-08-11336,13501,321,62925.4%
2025-08-08485,2572001,830,29826.5%
2025-08-07801,2735,6304,409,96418.2%
2025-08-06926,71803,689,58625.1%
2025-08-05811,11602,559,41531.7%
2025-08-04894,07898,9894,200,95221.3%
2025-08-011,671,90054,69312,502,18913.4%
2025-07-31823,47802,928,54928.1%
2025-07-301,135,0252,3584,670,48324.3%
2025-07-29244,8102101,095,85522.3%
2025-07-28387,7862,4071,088,25435.6%
2025-07-25405,26398,1741,551,84726.1%
2025-07-24587,91633,1922,074,22128.3%
2025-07-23948,5721,5003,643,60926.0%
2025-07-22410,8244001,505,84527.3%
2025-07-21366,20401,807,98520.3%
2025-07-18374,76501,763,18621.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.